oki-219
·Code: OKI-219
oki-219: developed by 1 company · 1 clinical trial tracked.
oki-219 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect oki-219 to OKUR; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could oki-219 → OKUR affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| OnKure Therapeutics, Inc. (OKUR) | Phase 1 |
Clinical Trials (1)
PIKture-01: First-in-Human Study of the PI3KαH1047R Mutant-Selective Inhibitor OKI-219 as Monotherapy in Participants With Advanced Solid Tumors and as Part of Combination Therapy in Participants With Advanced Breast Cancer
Primary endpoint: Identify maximum tolerated dose (MTD) of OKI-219 in monotherapy
InterventionalRandomizedopen200 targetStarted 2024-02Completion 2027-0833 sites · Belgium, France, Italy, South Korea…OnKure, Inc.
Frequently asked questions
Who is developing oki-219?
oki-219 is being developed by OnKure Therapeutics, Inc..
How many clinical trials involve oki-219?
BioSniper tracks 1 clinical trial involving oki-219.